Reader TTS

A new systematic review detected strong evidence of unreliable results via use of statistical and logical analyses of 33 randomized clinical trials. Our outrage at these rare occurrences of

potential fraud could be rooted in our disdain at our failures in peer review, given that this special effort was required to detect long-running potential fraud. Access through your

institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES *

Bolland, M. J., Avenell, A., Gamble, G. & Grey, A. Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. _Neurology_ 87, 1–12 (2016). Article 

Google Scholar  * Bailey, K. Detecting fabrication of data in a multicenter collaborative animal study. _Control. Clin. Trials_ 12, 741–752 (1991). Article  CAS  Google Scholar  * DeMets, D.

Distinctions between fraud, bias, errors, misunderstanding, and incompetence. _Control. Clin. Trials_ 18, 637–650 (1997). Article  CAS  Google Scholar  Download references AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Department of Biostatistics, Gary R. Cutter is at the UAB School of Public Health, 1667 University Boulevard, Ryals Building Room 410b, Birmingham,

Alabama 35243, USA., Gary R. Cutter Authors * Gary R. Cutter View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Gary

R. Cutter. ETHICS DECLARATIONS COMPETING INTERESTS The author is on Data and Safety Monitoring Boards for AMO Pharma Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals,

Modigenetech/Prolor, Merck, Merck/Pfizer, Neuren, Opko Biologics, Reata Pharmaceuticals, Receptos/Celgene, Sanofi-Aventis, Teva pharmaceuticals, National Heart Lung and Blood Institute

(Protocol Review Committee), National Institute of Child Health and Development (OPRU oversight committee). He runs MS Patient Registry, which receives a grant from Consortium of MS Centers.

Moreover, he is on Consulting or Advisory Boards for Cerespir, Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis,

Novartis, Opexa Therapeutics, Roche, Savara, Somahlution, Teva Pharmaceuticals, Transparency Life Sciences, and TG Therapeutics. He is President of Pythagoras, a private consulting company

located in Birmingham, Alabama, USA. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Cutter, G. To catch a crook, you might try statistics. _Nat Rev

Neurol_ 13, 9–10 (2017). https://doi.org/10.1038/nrneurol.2016.194 Download citation * Published: 16 December 2016 * Issue Date: January 2017 * DOI: https://doi.org/10.1038/nrneurol.2016.194

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy

to clipboard Provided by the Springer Nature SharedIt content-sharing initiative